Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1996 Apr;40(4):1020–1023. doi: 10.1128/aac.40.4.1020

Quinolone-resistant Neisseria gonorrhoeae: correlation of alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV with antimicrobial susceptibility profiles.

T Deguchi 1, M Yasuda 1, M Nakano 1, S Ozeki 1, T Ezaki 1, I Saito 1, Y Kawada 1
PMCID: PMC163251  PMID: 8849219

Abstract

Fifty-five clinical strains of Neisseria gonorrhoeae were examined for mutations in the gyrA and parC genes and for antimicrobial susceptibility profiles. The MICs of quinolones for 31 strains with alterations in GyrA were significantly higher than the MICs for 24 strains without such alterations. Eleven strains with alterations in both GyrA and ParC were significantly more resistant to fluoroquinolones than those with alterations in GyrA alone. The MICs of cephalosporins for these strains were also significantly higher than those for other strains.

Full Text

The Full Text of this article is available as a PDF (182.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Belland R. J., Morrison S. G., Ison C., Huang W. M. Neisseria gonorrhoeae acquires mutations in analogous regions of gyrA and parC in fluoroquinolone-resistant isolates. Mol Microbiol. 1994 Oct;14(2):371–380. doi: 10.1111/j.1365-2958.1994.tb01297.x. [DOI] [PubMed] [Google Scholar]
  2. Deguchi T., Yasuda M., Asano M., Tada K., Iwata H., Komeda H., Ezaki T., Saito I., Kawada Y. DNA gyrase mutations in quinolone-resistant clinical isolates of Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1995 Feb;39(2):561–563. doi: 10.1128/aac.39.2.561. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ferrero L., Cameron B., Manse B., Lagneaux D., Crouzet J., Famechon A., Blanche F. Cloning and primary structure of Staphylococcus aureus DNA topoisomerase IV: a primary target of fluoroquinolones. Mol Microbiol. 1994 Aug;13(4):641–653. doi: 10.1111/j.1365-2958.1994.tb00458.x. [DOI] [PubMed] [Google Scholar]
  4. Gorwitz R. J., Nakashima A. K., Moran J. S., Knapp J. S. Sentinel surveillance for antimicrobial resistance in Neisseria gonorrhoeae--United States, 1988-1991. The Gonococcal Isolate Surveillance Project Study Group. MMWR CDC Surveill Summ. 1993 Aug 13;42(3):29–39. [PubMed] [Google Scholar]
  5. Ison C. A., Tekki N., Gill M. J. Detection of the tetM determinant in Neisseria gonorrhoeae. Sex Transm Dis. 1993 Nov-Dec;20(6):329–333. [PubMed] [Google Scholar]
  6. Rice R. J., Knapp J. S. Susceptibility of Neisseria gonorrhoeae associated with pelvic inflammatory disease to cefoxitin, ceftriaxone, clindamycin, gentamicin, doxycycline, azithromycin, and other antimicrobial agents. Antimicrob Agents Chemother. 1994 Jul;38(7):1688–1691. doi: 10.1128/aac.38.7.1688. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Stein D. C., Danaher R. J., Cook T. M. Characterization of a gyrB mutation responsible for low-level nalidixic acid resistance in Neisseria gonorrhoeae. Antimicrob Agents Chemother. 1991 Apr;35(4):622–626. doi: 10.1128/aac.35.4.622. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Tanaka M., Kumazawa J., Matsumoto T., Kobayashi I. High prevalence of Neisseria gonorrhoeae strains with reduced susceptibility to fluoroquinolones in Japan. Genitourin Med. 1994 Apr;70(2):90–93. doi: 10.1136/sti.70.2.90. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Yoshida H., Bogaki M., Nakamura M., Nakamura S. Quinolone resistance-determining region in the DNA gyrase gyrA gene of Escherichia coli. Antimicrob Agents Chemother. 1990 Jun;34(6):1271–1272. doi: 10.1128/aac.34.6.1271. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES